Clinical trials: Type 2 Diabetes Mellitus
- Condition Type 2 Diabetes Mellitus
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- AWARD-JPN (NCT04809220)
- Testing
- Dulaglutide, Oral antihyperglycemics
- Where
- 44 sites in Japan
- Volunteers
- 591 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together.
- Trial name
- NCT01408888
- Testing
- LY2189265, Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise…
- Trial name
- NCT02577003
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg metformin IR tablet co-administered to…
- Trial name
- NCT00899470
- Testing
- Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04937319 following single escalating oral doses in adult subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT01044537
- Testing
- PF-04937319
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
- Trial name
- NCT04285983
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes.
- Trial name
- NCT05813912
- Testing
- Insulin Icodec, Semaglutide
- Where
- 39 sites in Czechia, Malaysia and 3 more
- Volunteers
- 148 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral…
- Trial name
- NCT01387737
- Testing
- TA-7284-Low, TA-7284-High
- Where
- 7 sites in Japan
- Volunteers
- 1,299 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes.
- Trial name
- IMAGINE 8 (NCT02132637)
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- 3 sites in United States, Germany
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
- Trial name
- PRONTO-T2D (NCT03214380)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 141 sites in United States, Argentina and 14 more
- Volunteers
- 933 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
- Trial name
- NCT01517373
- Testing
- PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05086445
- Testing
- LY3502970
- Where
- 5 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
to determine safety, efficacy and tolerability of BI 1356 versus placebo
- Trial name
- NCT00800683
- Testing
- BI 1356
- Where
- 53 sites in United States, Australia and 4 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
- Trial name
- NCT00541775
- Testing
- Sitagliptin, Comparator: Rosiglitazone, Comparator: Metformin
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.
- Trial name
- FLOW (NCT03819153)
- Testing
- Semaglutide
- Where
- 413 sites in United States, Argentina and 26 more
- Volunteers
- 3,533 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)
This study will assess the effect of combined treatment with MK0893 plus propranolol versus placebo plus propranolol on hypoglycemia.
- Trial name
- NCT00902161
- Testing
- MK0893, Propranolol Hydrochloride (HCL)
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341312
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or…
- Trial name
- NCT00660309
- Testing
- Aliskiren, Irbesartan, Captopril
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
- Trial name
- NCT00736099
- Testing
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Where
- 232 sites in United States, Argentina and 30 more
- Volunteers
- 2,122 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).
- Trial name
- NCT02916706
- Testing
- Teneligliptin 20mg
- Where
- China
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation